AbbVie (NYSE:ABBV) Stock Price Up 1.9% – Time to Buy?

AbbVie Inc. (NYSE:ABBV)’s share price shot up 1.9% during mid-day trading on Monday . The company traded as high as $228.30 and last traded at $227.5340. 5,921,908 shares traded hands during trading, a decline of 7% from the average session volume of 6,334,500 shares. The stock had previously closed at $223.32.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ABBV. JPMorgan Chase & Co. increased their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Bank of America boosted their price objective on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Wells Fargo & Company upped their target price on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Finally, Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $244.55.

AbbVie Stock Up 1.9%

The firm has a market cap of $402.14 billion, a P/E ratio of 172.37, a P/E/G ratio of 1.21 and a beta of 0.36. The firm’s fifty day moving average is $227.25 and its 200 day moving average is $209.95. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period last year, the business posted $3.00 earnings per share. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio is presently 524.24%.

Institutional Investors Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently modified their holdings of ABBV. Mirabella Financial Services LLP increased its position in AbbVie by 154.7% during the third quarter. Mirabella Financial Services LLP now owns 32,899 shares of the company’s stock worth $7,602,000 after acquiring an additional 19,980 shares during the period. Farmers National Bank grew its position in shares of AbbVie by 66.5% during the 3rd quarter. Farmers National Bank now owns 14,178 shares of the company’s stock worth $3,283,000 after purchasing an additional 5,664 shares in the last quarter. Hudson Bay Capital Management LP grew its position in shares of AbbVie by 24.1% during the 3rd quarter. Hudson Bay Capital Management LP now owns 69,352 shares of the company’s stock worth $16,058,000 after purchasing an additional 13,466 shares in the last quarter. Alecta Tjanstepension Omsesidigt increased its holdings in shares of AbbVie by 10.5% during the third quarter. Alecta Tjanstepension Omsesidigt now owns 1,158,900 shares of the company’s stock worth $268,262,000 after purchasing an additional 110,300 shares during the period. Finally, Allworth Financial LP raised its position in shares of AbbVie by 14.1% in the third quarter. Allworth Financial LP now owns 243,834 shares of the company’s stock valued at $56,457,000 after buying an additional 30,124 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.